Our study was designed to directly compare the effect of an SGLT2 inhibitor empagliflozin on the changes of CKD-MBD biomarkers between diabetic and non-diabetic patients with CKD. The gene discussed is SLC5A2; the disease is Marchiafava-Bignami disease.